Bone metastases, also called osseous metastases, are common secondary tumors formed by cancer cells that have spread from a primary tumor to the bone through blood circulation or lymphatic system. Solid tumors such as breast cancer, prostate cancer, lung cancer and renal cell cancer commonly metastasize to bone. Bone-modifying agents are used as the standard treatment of bone metastases to prevent skeletal-related events such as pathological fractures or improve pain. These agents inhibit bone breakdown or promote bone formation to maintain bone structure and strength when bones are weakened by tumor growth.
The bone metastasis in solid tumors market is estimated to be valued at USD 3.8 billion in 2024 and is expected to reach USD 6.73 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Key players operating in the bone metastases in solid tumors market are Novartis AG, Amgen Inc., Pfizer Inc., Bayer AG, Pharmalucence Inc.
Increasing R&D activities to develop advanced treatment options and growing awareness about metastatic cancer treatment are some of the key opportunities in the Bone Metastasis in Solid Tumors Market. Major companies are focusing on expanding their geographic presence through collaborations and acquisitions of regional players to strengthen their global footprint in key emerging markets including Asia Pacific and Latin America.
Market Drivers
Rising preference for minimally invasive treatment alternatives over palliative radiotherapy or orthopedic stabilization procedures is a major market driver. Complex surgeries for spine or long bone reconstruction are being replaced by simpler interventions like vertebroplasty or kyphoplasty which restore spinal integrity and reduce pain.
Market Restrains
High cost of advanced bone-targeting agents and lack of insurance coverage for new drugs in some developing regions are key challenges restraining faster market growth. Biosimilars are still not widely adopted as a lower-cost treatment option.
Segment Analysis
The global bone metastasis in solid tumor market can be segmented into breast cancer, prostate cancer, lung cancer, thyroid cancer, kidneys cancer and others. Among them, the breast cancer segment dominates the market currently owing to its high prevalence rate globally. Breast cancer accounts for 30% of all new cancer cases diagnosed in women worldwide and is the leading cause of cancer deaths in women globally according to WHO. It has high propensity to spread to bones. According to American Cancer Society's estimates, over 231,840 new cases of invasive breast cancer will be diagnosed in women in the United States along with over 40,000 deaths in 2021.
Global Analysis
Regionally, North America holds the largest share in bone metastasis in solid tumor market due to rising healthcare expenditures and growing diagnoses. According to Cancer Research UK, Europe accounts for the second largest share due to increasing public healthcare funding. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period owing to growing medical tourism, rising healthcare spending and cancer incidence rates. China, Japan and India represent large patient populations suffering from solid tumor cancers which further boosts the market growth.
Get this Report in Japanese Language: 固形がんの骨転移市場
Get this Report in Korean Language: 고형 종양 시장에서의 골 전이
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
